# Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis

> **NCT03298581** · PHASE2 · WITHDRAWN · sponsor: **Sun Pharmaceutical Industries Limited**

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Halobetasol Propionate

## Key facts

- **NCT ID:** NCT03298581
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01-01
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2021-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298581, "Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03298581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*